

# Combining Data from Different Sources in Risk Assessment

Daniel Krewski, PhD, MHA  
Professor and Director  
McLaughlin Centre for  
Population Health Risk Assessment  
&  
Risk Sciences International

EPA IRIS Workshop  
October 16, 2014

Université d'Ottawa | University of Ottawa



uOttawa

L'Université canadienne  
Canada's university



[www.uOttawa.ca](http://www.uOttawa.ca)

# Outline

---

- Systematic review of available data
- Meta-analysis of summary risk estimates
- Combined analysis of primary raw data
- Categorical regression of toxicity severity scores
- Conclusions

# Systematic Review

---

**Critical Reviews  
in Toxicology**

<http://informahealthcare.com/txc>  
ISSN: 1040-8444 (print), 1547-6898 (electronic)

Crit Rev Toxicol, 2014; Early Online: 1–81  
© 2014 Informa Healthcare USA, Inc. DOI: 10.3109/10408444.2014.934439

**informa**  
healthcare

---

REVIEW ARTICLE

## Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts

Calvin C. Willhite<sup>1,2</sup>, Nataliya A. Karyakina<sup>1</sup>, Robert A. Yokel<sup>3</sup>, Nagarajkumar Yenugadhati<sup>2</sup>, Thomas M. Wisniewski<sup>4</sup>, Ian M.F. Arnold<sup>5</sup>, Franco Momoli<sup>6,7,8</sup>, and Daniel Krewski<sup>1,2,7</sup>


*Comprehensive and reproducible*

# Meta-analysis

## A meta-analysis of observational studies of the association between chronic occupational exposure to lead and amyotrophic lateral sclerosis

Ming-Dong Wang, PhD; James Gomes, PhD; Neil R. Cashman, MD; Julian Little, PhD; Daniel Krewski, PhD

(to appear in *Journal of Occupational and Environmental Medicine*, 2014)



*Estimating the risks*

# Quality Scoring of Observational Studies

---

## **A Systematic Review and Meta-analysis of Childhood Leukemia and Parental Occupational Pesticide Exposure**

*Donald T. Wigle, Michelle C. Turner, and Daniel Krewski*

McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, Ontario, Canada

Environmental Health Perspectives • VOLUME 117 | NUMBER 10 | October 2009

### *Quality scoring of cohort studies*

## **Residential Pesticides and Childhood Leukemia: A Systematic Review and Meta-Analysis**

*Michelle C. Turner,<sup>1,2</sup> Donald T. Wigle,<sup>1</sup> and Daniel Krewski<sup>1,3,4</sup>*

<sup>1</sup>McLaughlin Centre for Population Health Risk Assessment, Institute of Population Health, <sup>2</sup>Faculty of Graduate and Postgraduate Studies, and <sup>3</sup>Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada; <sup>4</sup>Risk Sciences International, Ottawa, Canada

Environmental Health Perspectives • VOLUME 118 | NUMBER 1 | January 2010

### *Quality scoring of case-control studies*

# Meta-analysis

---

OPEN ACCESS Freely available online



## Intermediate CAG Repeat Expansion in the *ATXN2* Gene Is a Unique Genetic Risk Factor for ALS—A Systematic Review and Meta-Analysis of Observational Studies

Ming-Dong Wang<sup>1\*</sup>, James Gomes<sup>1</sup>, Neil R. Cashman<sup>2</sup>, Julian Little<sup>1\*</sup>, Daniel Krewski<sup>1\*</sup>

<sup>1</sup> Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada, <sup>2</sup> Department of Medicine, University of British Columbia, Vancouver, Canada

*Discovering new relationships*

# Systematic Review of Factors Affecting the Onset and Progression of Neurological Conditions

---

- ALS
- Alzheimer's disease
- Brain cancer
- Cerebral palsy
- Dystonia
- Epilepsy
- Huntingdon's disease
- Hydrocephalus
- Neurotrauma
- Multiple sclerosis
- Muscular dystrophies
- Parkinson's disease
- Spina biffeda
- Tourette's syndrome

*Consider pre-existing systematic reviews to reduce the volume of work (with AMSTAR scoring)*

# Risk Factors Possibly Affecting the Onset of Priority Neurological Conditions

| Biological                           | Genetic  | Environmental/<br>Occupational   | Lifestyle | Psychosocial/Social | Pharmacological | Demographic |
|--------------------------------------|--|--|-----------|---------------------|-----------------|-------------|
| <b>Amyotrophic Lateral Sclerosis</b> |  |  |           |                     |                 |             |
|                                      | <ul style="list-style-type: none"> <li>• SOD1 monogenic mutation</li> <li>• C9ORF72 SOD1 monogenic mutation</li> <li>• ATAXIN 2</li> </ul> | <ul style="list-style-type: none"> <li>• Pesticides</li> <li>• Heavy metals such as lead</li> <li>• Organic solvents</li> <li>• Previous trauma</li> <li>• Electric shock</li> </ul> |           |                     |                 |             |
| <b>Alzheimer's Disease</b>           |  |  |           |                     |                 |             |

Classify weight of evidence as **sufficient** , **limited**, or **inadequate** using simplified criteria

*Systematic review summarizes the evidence, but does not necessarily weigh the evidence*



# Combined Analysis of Primary Raw Data

---

## Residential Radon and Risk of Lung Cancer


### *A Combined Analysis of 7 North American Case-Control Studies*

*Daniel Krewski,<sup>\*</sup> Jay H. Lubin,<sup>†</sup> Jan M. Zielinski,<sup>\*\*</sup> Michael Alavanja,<sup>§</sup> Vanessa S. Catalan,<sup>||</sup>  
R. William Field,<sup>\*\*\*</sup> Judith B. Klotz,<sup>††</sup> Ernest G. Létourneau,<sup>‡‡</sup> Charles F. Lynch,<sup>¶</sup> Joseph I. Lyon,<sup>§§</sup>  
Dale P. Sandler,<sup>||</sup> Janet B. Schoenberg,<sup>††</sup> Daniel J. Steck,<sup>¶¶</sup> Jan A. Stolwijk,<sup>\*\*\*\*</sup> Clarice Weinberg,<sup>†††</sup>  
and Homer B. Wilcox<sup>††</sup>*

*Epidemiology* • Volume 16, Number 2, March 2005

*Explore modifying factors and heterogeneity*

# Exposure-response Curves for Individual and Combined Studies



Radon Concentration (Bq/m<sup>3</sup>)

# Categorical Regression


---

“An empirical modeling approach that involves the application of regression analysis and the organization of response data in the form of ordered categories of severity in order to predict the probability of achieving a particular severity category as a function of one or more independent variables (i.e., duration and concentration).”

- US EPA CatReg Manual

- Can be used to model *multiple studies and endpoints* simultaneously using a common toxicity metric

# Dose-response relationships for essential trace elements are complex



# Copper Dose-response Modeling: Phase I



Copper Dose-response Working Group (2002)

# Criteria Used for Exclusion of Studies


| Most Useful ←————→ Least Useful  |   |  |  |            |
|--|---|--|--|------------|
| 1  | 2   | 3  | 4  | 5          |
| Multiple dose or multiple outcomes from intact animals or humans<br><br>Adequate Reporting<br><br>Physiological Measures | Multiple or single dose from intact animals or humans<br><br>Fairly Good Reporting<br><br>Likely to yield useful information<br><br>Change in time Points<br><br>Cellular effects | Single dose or clinical study / case report with indeterminate dose<br><br>Tracer or PK Study<br><br>Info re. body burden or kinetics<br><br>Mechanistic or cellular effects | No dose information<br><br>Physiological information<br><br>Review | No Utility |

# Selection of Studies

(Phase I: studies published through to 2002)

---

~600 Papers



# Severity Scoring


| <u>Deficiency Endpoints</u>   | <u>Severity Score</u> | <u>Toxicity Endpoints</u>  |
|---|-----------------------|--|
| Cu burden; metallothionein; urine Cu  | 0                     | Cu burden; metallothionein; urine Cu   |
| Loss of Cu-dependent enzyme function (SOD); Changed blood cell number or function   | 1                     | Changes in cholesterol and triglyceride levels in blood/liver; large Cu burden; body weight; nausea; diarrhea; enzyme changes without histopathology |
| Organ weight changes; plasma glucose/insulin; heart rate; EKG changes; minor histopathology; white blood cell activity/counts | 2                     | Body weight; anemia; hemolysis; vitamin levels; liver enzymes; inflammation; organ weight changes  |
| Mortality; gross histopathology reproductive function changes   | 3                     | Death; gross histopathology  |



Metabolic perturbations

# Essentiality

Metabolic perturbations



Gross deficiency

Loss of Cu enzyme activity

Molecular manifestations

Molecular manifestations

Loss of Cu enzyme activity

Gross excess

# Copper Toxicity Database (Phase I)

---

*Journal of Toxicology and Environmental Health, Part A*, 73:208–216, 2010

Copyright © Taylor & Francis Group, LLC

ISSN: 1528-7394 print / 1087-2620 online

DOI: 10.1080/15287390903340815



## DEVELOPMENT OF A COPPER DATABASE FOR EXPOSURE-RESPONSE ANALYSIS

Daniel Krewski<sup>1</sup>, Andrea Chambers<sup>1</sup>, Bonnie Ransom Stern<sup>2</sup>, Peter J. Aggett<sup>3</sup>, Laura Plunkett<sup>4</sup>, Larisa Rudenko<sup>5</sup>

<sup>1</sup>McLaughlin Centre for Population Health Risk Assessment, Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada

<sup>2</sup>Consulting in Health Sciences and Risk Assessment, BR Stern and Associates, LLC, Annandale, Virginia, USA

<sup>3</sup>Emeritus Professor, Parbold, United Kingdom

<sup>4</sup>Integrative Biostrategies, LLC, Houston, Texas, USA

<sup>5</sup>Integrative Biostrategies, LLC, Washington, DC, USA

# Copper Toxicity Database (Phase I): Number of Observations by Species and Severity Level

---

| Factor         | Number of observations |        |
|----------------|------------------------|--------|
|                | Deficiency             | Excess |
| Severity level |                        |        |
| 0              | 59                     | 83     |
| 1              | 5                      | 6      |
| 2              | 18                     | 4      |
| 3              | 48                     | 16     |
| 4              | 6                      | 76     |
| Animal species |                        |        |
| Humans         | 8                      | 22     |
| Rats           | 108                    | 117    |
| Mice           | 18                     | 40     |
| Pigs           | 2                      | 6      |


---

# Copper Toxicity Database (Phase I): Data Displayed by Excess/Deficiency, Species, and Severity

Deficiency/Excess

Deficiency

Excess



**FIGURE 2.** Copper excess and deficiency data, copper deficiency data and copper excess data on humans (a-c), rats (d-f), and mice (g-i), respectively. Concentration is defined in mg/kg bw/d and duration is defined in days. Data points are represented as: ○ – severity level 0, ▽ – severity level 1, ◇ – severity level 2, ■ – severity level 3, ● – severity level 4.

# Copper Dose-response Modeling (Phase I)

---

*Journal of Toxicology and Environmental Health, Part A*, 73: 1–15, 2010

Copyright © Taylor & Francis Group, LLC

ISSN: 1528-7394 print / 1087-2620 online

DOI: 10.1080/15287390903340781




## The Use of Categorical Regression in Modeling Copper Dose-Response Relationships

**Daniel Krewski<sup>1</sup>, Andrea Chambers<sup>1</sup>, and Nicholas Birkett<sup>2</sup>**

*<sup>1</sup>McLaughlin Centre for Population Health Risk Assessment, Institute of Population Health, University of Ottawa, Ottawa, Ontario, and <sup>2</sup>McLaughlin Centre for Population Health Risk Assessment and Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada*

# ED10 Dose - Duration Curves for Severity Level 3 for Toxicity due to Copper Excess



# Interspecies Scaling

---

- Interspecies scaling based on four dose metrics:

Body weight: mg/kg bw/day

Surface area:  $bw^{2/3}$

Intermediate:  $bw^{3/4}$  (*Travis & White, 1988*)

Total intake: mg/day

# Copper Dose-response Modeling: Phase II



**Copper Dose-response Working Group (2009)**



|      |                   | Severity Score                | Response  |
|------|-------------------|-------------------------------|---|
| AROI | Copper Excess     | 6                             | Death   |
|      |                   | 5                             | Irreversible Gross Excess                         |
|      |                   | 4                             | Reversible Gross Excess                           |
|      |                   | 3                             | Metabolic Perturbation                            |
|      |                   | 2                             | Early Biological Indicators Altered Cu Metabolism |
|      |                   | 1                             | Homeostatic Adaptation to High Intakes            |
|      | No Effect         | 0                             | No change compare to controls                     |
|      |                   | 0                             |   |
|      | Copper Deficiency | 1                             | Homeostatic Adaptations to Low Intakes            |
|      |                   | 2                             | Early Biological Indicators of Def Cu Levels      |
|      |                   | 3                             | Metabolic Perturbation                            |
|      |                   | 4                             | Reversible Gross Deficiency                       |
| 5    |                   | Irreversible Gross Deficiency |   |
|      | 6                 | Death                         |   |

*Journal of Toxicology and Environmental Health, Part B*, 13:546–578, 2010  
Copyright © Taylor & Francis Group, LLC  
ISSN: 1093-7404 print / 1521-6950 online  
DOI: 10.1080/10937404.2010.538657



## AN EXPOSURE-RESPONSE CURVE FOR COPPER EXCESS AND DEFICIENCY

Andrea Chambers<sup>1</sup>, Daniel Krewski<sup>1</sup>, Nicholas Birkett<sup>1,2</sup>, Laura Plunkett<sup>3</sup>, Richard Hertzberg<sup>4</sup>,  
Ruth Danzeisen<sup>5</sup>, Peter J. Aggett<sup>6</sup>, Thomas B. Starr<sup>7</sup>, Scott Baker<sup>5</sup>, Michael Dourson<sup>8</sup>,  
Paul Jones<sup>9</sup>, Carl L. Keen<sup>10</sup>, Bette Meek<sup>11</sup>, Rita Schoeny<sup>12</sup>, Wout Slob<sup>13</sup>

# Number of Observations by Species and Severity Score

| <i>Factor</i>            | Severity Levels |          |          |          |          |          |          |
|--------------------------|-----------------|----------|----------|----------|----------|----------|----------|
|                          | <i>0</i>        | <i>1</i> | <i>2</i> | <i>3</i> | <i>4</i> | <i>5</i> | <i>6</i> |
| <b>Copper Excess</b>     |                 |          |          |          |          |          |          |
| Humans                   | 12 (28)         | 0        | 4 (5)    | 0        | 6 (13)   | 0        | 0        |
| Rats                     | 7 (55)          | 0 (8)    | 0 (3)    | 2 (17)   | 4 (46)   | 0 (3)    | 0 (4)    |
| Mice                     | 2 (21)          | 0        | 0        | 2 (4)    | 0 (14)   | 0        | 0 (5)    |
| Pigs                     | 8 (8)           | 0        | 3 (3)    | 3 (3)    | 0        | 0        | 0        |
| Rabbits                  | 1 (1)           | 0        | 0        | 1 (1)    | 0        | 0        | 0        |
| <b>Copper Deficiency</b> |                 |          |          |          |          |          |          |
| Humans                   | 2 (5)           | 2 (3)    | 0 (3)    | 1 (2)    | 0        | 0        | 0        |
| Rats                     | 27 (74)         | 6 (10)   | 6 (22)   | 21 (64)  | 5 (6)    | 0        | 0 (1)    |
| Mice                     | 2 (11)          | 6 (0)    | 0 (1)    | 2 (2)    | 0 (4)    | 0        | 0        |
| Pigs                     | 0 (1)           | 0        | 0        | 0 (1)    | 0        | 0        | 0        |

\* Bolded values represent the number of observations added from the literature review update and values in parenthesis represent the total number of observations including those identified prior to 2002.

# Goodness of Fit Under Alternative Model Specifications

TABLE 5. AIC for 24 Modeling Options for Copper Excess and Deficiency

| Link Function | C      | T      | AIC        |        |
|---------------|--------|--------|------------|--------|
|               |        |        | Deficiency | Excess |
| Logit         | Linear | Linear | 514.3146   | 576.76 |
| Logit         | Linear | Log    | 511.2093   | 574.78 |
| Logit         | Log    | Linear | 514.3866   | 547.11 |
| Logit         | Log    | Log    | 511.1258   | 541.52 |
| Probit        | Linear | Linear | 518.7908   | 579.49 |
| Probit        | Linear | Log    | 517.7919   | 579.79 |
| Probit        | Log    | Linear | 518.8718   | 574.04 |
| Probit        | Log    | Log    | 517.8761   | 543.70 |
| C Log-log     | Linear | Linear | 514.5548   | NA*    |
| C Log-log     | Linear | Log    | 505.7347   | NA*    |
| C Log-log     | Log    | Linear | 514.6525   | NA*    |
| C Log-log     | Log    | Log    | 505.8695   | NA*    |

# Model Stratification Options (Species, Exposure Medium, Age)

TABLE 6. Stratification Options in the Cumulative Odds Model for the Copper Excess and Copper Deficiency Data

| Stratification Option                                   | Chi-square | df | P-value |
|---|------------|----|---------|
| <b>Copper Excess:</b>                                   |            |    |         |
| Intercept Stratified by Animal Species <sup>a</sup>     | 20.98      | 4  | <0.05   |
| Intercept Stratified by Exposure Medium <sup>b</sup>    | 7.07       | 3  | <0.05   |
| Concentration Stratified by Animal Species <sup>c</sup> | 8.07       | 3  | <0.05   |
| Concentration Stratified by Age <sup>b</sup>            | 11.40      | 2  | <0.05   |
| <b>Copper Deficiency:</b>                               |            |    |         |
| Intercept Stratified by Animal Species <sup>c</sup>     | 83.62      | 3  | <0.0001 |
| Intercept Stratified by Age <sup>b</sup>                | 11.93      | 2  | <0.01   |

# Cumulative Odds Model for Copper Excess

**TABLE 7.** Parameter Estimates, Standard Errors, Z-test Statistics and P-values for Copper Excess Studies Using the Cumulative Odds Model\*

| Parameter      | <i>Estimate</i> | <i>Std. Error</i> | <i>Z-test</i> | <i>P-value</i> |
|----------------|-----------------|-------------------|---------------|----------------|
| SEV1           | 5.8797          | 3.1609            | 1.8601        | 0.0629         |
| SEV2           | 5.4416          | 3.2080            | 1.6963        | 0.0898         |
| SEV3           | 5.0383          | 3.2206            | 1.5644        | 0.1177         |
| SEV4           | 4.0248          | 3.2062            | 1.2553        | 0.2094         |
| HU:F:INTERCEPT | 0.0000          | 0.0000            | NA            | NA             |
| HU:W:INTERCEPT | 1.9743          | 1.2831            | 1.5387        | 0.1239         |
| MU:F:INTERCEPT | -19.1012        | 7.6620            | -2.4930       | 0.0127         |
| MU:W:INTERCEPT | -15.6647        | 5.9865            | -2.6167       | 0.0089         |
| RT:F:INTERCEPT | -13.8327        | 3.1243            | -4.4274       | <0.0001        |
| RT:W:INTERCEPT | -12.9416        | 3.2232            | -4.0152       | <0.0001        |
| HU:2:LG10CONC  | 9.7482          | 2.8460            | 3.4252        | 0.006          |
| MU:1:LG10CONC  | 5.8122          | 3.7392            | 1.5544        | 0.1201         |
| MU:2:LG10CONC  | 3.8369          | 2.4670            | 1.5537        | 0.1203         |
| RT:1:LG10CONC  | 3.2419          | 0.4016            | 8.0731        | <0.0001        |
| RT:2:LG10CONC  | 2.4122          | 0.3361            | 7.17777       | <0.0001        |
| LG10TIME       | 2.5437          | 0.6976            | 3.6463        | <0.001         |

\* Cumulative odds model uses the logit link function. Concentration (mg/kg bw/days) and duration (days) have been log transformed to the base 10. Note. SEV, severity level; LG10, log transformed to the base 10; CONC, concentration coefficient; TIME, duration coefficient; HU, humans; RT, rats; MU, mice; F, dietary studies; W, drinking water studies; 1, young animal ( $\leq 30$  days of age); 2, mature animal ( $> 30$  days of age for rodents and  $\geq 18$  years for humans).


# Cumulative Odds Model for Copper Deficiency

TABLE 8. Parameter Estimates, Standard Errors, Z-test Statistics and P-values for the Cumulative Odds Model\* of the Copper Deficiency Data

| <i>Parameter</i> | <i>Estimate</i> | <i>Std. Error</i> | <i>Z-test</i> | <i>P-value</i> |
|------------------|-----------------|-------------------|---------------|----------------|
| SEV1             | -9.7115         | 1.7215            | -5.6414       | <0.0001        |
| SEV2             | -10.5141        | 1.7354            | -6.0585       | <0.0001        |
| SEV3             | -11.7843        | 1.7663            | -6.6720       | <0.0001        |
| SEV4             | -15.8934        | 1.9502            | -8.1498       | <0.0001        |
| HU:2:INTERCEPT   | 0.0000          | 0.0000            | NA            | NA             |
| MU:1:INTERCEPT   | 9.2461          | 1.7256            | 5.3583        | <0.0001        |
| MU:2:INTERCEPT   | 7.6482          | 1.0245            | 7.4655        | <0.0001        |
| RT:1:INTERCEPT   | 6.7146          | 0.7683            | 8.7391        | <0.0001        |
| RT:2:INTERCEPT   | 4.6963          | 0.6322            | 7.4285        | <0.0001        |
| LG10CONC         | -5.2314         | 0.5517            | -9.4817       | <0.0001        |
| LG10TIME         | 0.2247          | 0.9321            | 0.2410        | 0.8095         |

\* Cumulative odds model uses the logit link function. Concentration (mg/kg bw/day) and duration (days) log transformed (log<sub>10</sub>). Note. SEV, severity level; LG10, log transformed to the base 10; CONC, concentration coefficient; TIME, duration coefficient; HU, humans; MU, mice; RT, rats; 2, mature animals (>30 days of age) or adult humans (≥18 years of age); 1 = young animals (≤30 days of age).

# Dose-Response Curves for Copper Deficiency and Excess





# Optimal Intake of Copper


---

Using this model, an optimal intake level of **2.6 mg Cu/day** was determined. This value is higher than the current US recommended dietary intake (RDI; **0.9 mg/day**) that protects against toxicity from copper deficiency. It is also lower than the current tolerable upper intake level (UL; **10 mg/day**) that protects against toxicity from copper excess.

Chambers et al. (2010)

# Extended Copper Dose-response Modeling

- *CatReg* was designed to model increasing relationships
- To model deficiency, it is necessary to impose an increasing relationship



- It is not possible to model excess and deficiency simultaneously

# A New Approach to Modeling U-shaped Curves

## *A Joint Model for Excess and Deficiency (JMED)*

Assuming the response variable has been dichotomized, the JMED is defined to capture dose concentration and origin of toxicity in one well-defined model.

Define

$x_{i1} = \log_{10}$  concentration of the  $i^{th}$  observation

$$x_{i2} = \begin{cases} 1, & \text{excess} \\ 0, & \text{deficiency} \end{cases}$$

The JMED model is expressed as:

$$\text{logit}[P(Y_i = 1)] = \beta_0 + \beta_1 x_{i1} + \beta_2 x_{i2} + \beta_3 x_{i1} x_{i2}$$

# JMED Components


The JMED is comprised of excess and deficiency components.

The log odds of a non-normal response for deficiency and excess, respectively, are:


$$\text{logit}[P_D(Y_i = 1)] = \beta_0 + \beta_1 x_{i1}$$

$$\text{logit}[P_E(Y_i = 1)] = \beta_0 + \beta_2 + (\beta_1 + \beta_3)x_{i1}$$

Assuming  $\beta_1 < 0$ ,  $\beta_3 > 0$ , and  $\beta_1 + \beta_3 > 0$ ,  
a display of  $\text{logit}[P_D(Y_i = 1)]$  and  
 $\text{logit}[P_E(Y_i = 1)]$  versus  $x_{i1}$  would appear  
as:



# Investigating the Point of Intersection



The intersection point between the excess and deficiency curves has been named the ***equiprobable crossover point (EPCP)***.


It is possible to obtain a closed form solution for the EPCP by equating  $\text{logit}[P_D(Y_i = 1)]$  and  $\text{logit}[P_E(Y_i = 1)]$ , and solving for  $x_{i1}$ .

$$EPCP = -\frac{\beta_2}{\beta_3}$$

The EPCP represents the concentration level where the probability of excess is equivalent to the probability of deficiency.

# The Independence Model

In addition to the EPCP, a second quantity of interest is the probability of excess or deficiency, or both.




The Independence Model is expressed as:

$$P_{DUE}(Y_i = 1) = P_D(Y_i = 1) + P_E(Y_i = 1) - P_D(Y_i = 1) P_E(Y_i = 1)$$

# The Independence Model: Investigating $x_{\text{MINDUE}}$

$x_{\text{MINDUE}}$  represents the dose that will minimize the probability of a departure from a normal reading.



There is no closed form solution for  $x_{\text{MINDUE}}$  → Solve numerically using Newton's Method

# Application of the JMED to Copper


- The inclusion of indicator variables for rats and mice facilitates a species-specific analysis where humans are considered the baseline
- Results developed for the general case EPCP and  $x_{\text{MINDUE}}$  will readily extend

$$x_{i3} = \begin{cases} 1, & \text{if mouse} \\ 0, & \text{otherwise} \end{cases} \quad x_{i4} = \begin{cases} 1, & \text{if rat} \\ 0, & \text{otherwise} \end{cases}$$

- Define

$$P(Y_i = 1) = \frac{\exp(\sum_{k=0}^9 x_{ik}\beta_k)}{1 + \exp(\sum_{k=0}^9 x_{ik}\beta_k)}$$


The species-stratified JMED is :





# Optimal Intake of Copper

U-Shape Curve for Humans



$$X_{\text{MINDUE}} = 2.73 \text{ mg/day}$$

For humans, a daily oral intake of **2.73 mg** will minimize the probability of a departure from a non-normal response attributed to excess or deficiency. The 95% confidence interval for  $X_{\text{MINDUE}}$  is (1.57, 4.46) and is analogous to an acceptable range of oral intakes.

# Conclusions

---

- **Systematic review** useful in summarizing the available evidence to support both hazard identification and risk estimation
- The results of the systematic review still needs to be evaluated with respect to both **quality** and **weight of evidence** for causality
- **Meta-analysis** and **combined analysis** useful for obtaining an overall summary measure of risk, based on good quality available data
- **Categorical regression** provides an approach to combining data from multiple studies on diverse endpoints in different test systems

# Possible New Paradigm for QRA:

$$SR + MA/CA/CR = \textit{Unit risk}$$

Summarize  
the  
evidence

Quantify  
the  
evidence

Best possible  
overall estimate  
of risk